New Oracle Health Sciences InForm and Oracle Argus Safety Integration Accelerates Safety Reporting, Reduces Costs
Out-of-the-Box Integration Automates Adverse Event Data Transfer Using E2B Standards to Increase Efficiency and Improve Safety Data Quality
To help clinical trial sponsors and contract research organizations (CROs) more cost-effectively and efficiently capture and manage information on adverse events, Oracle has integrated
Adverse event information from Oracle Health Sciences InForm is now available to safety teams within minutes as opposed to hours or days, allowing sponsors and CROs to assess potential SAEs faster and facilitate compliance with regulatory reporting requirements. Organizations can also save valuable time at the end of an electronic data capture (EDC) trial by avoiding time-consuming reconciliations between data across the clinical data management and safety systems. This closed-loop solution is designed to improve cross-organizational communication and provides up-to-date information by returning Oracle Argus Safety case numbers and status notifications back to Oracle Health Sciences InForm.
“Out-of-the-box integration between Oracle Health Sciences InForm and Oracle Argus Safety helps trial sponsors and CROs to respond faster to potential SAEs while reducing the costs and potential for error involved in rekeying information. It also ensures consistent information between the clinical data management and safety systems, which expedites data validation at the end of a trial, ultimately accelerating time to regulatory submission,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025